CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Comparative Clinical Outcomes of Paclitaxel- and Sirolimus-Eluting StentsResults From a Large Prospective Multicenter Registry—STENT Group
Charles A. Simonton, MD, FACC, FSCAI*,*,
Bruce Brodie, MD ,
Barrett Cheek, MD ,
Fred Krainin, MD ,
Chris Metzger, MD||,
James Hermiller, MD#,
Stanley Juk, MD**,
Peter Duffy, MD,
Angela Humphrey, MS,
Marcy Nussbaum, MS,
Sherry Laurent, PhD STENT Group
* Carolinas Heart Institute, Carolinas Medical Center, Charlotte, North Carolina
LeBauer Cardiovascular Research Foundation, Greensboro, North Carolina
High Point Regional Health System, High Point, North Carolina
McLeod Regional Medical Center, Florence, South Carolina
|| Holston Valley Medical Center, Kingsport, Tennessee
# Indiana Heart Institute, Indianapolis, Indiana
** Sisters of Charity Providence Hospitals, Columbia, South Carolina
Moore Regional Hospital, Pinehurst, North Carolina
R. Stuart Dickson Institute for Health Studies, Carolinas Medical Center, Charlotte, North Carolina
Manuscript received March 20, 2007;
revised manuscript received May 29, 2007,
accepted June 18, 2007.
* Reprint requests and correspondence: Dr. Charles A. Simonton, Sanger Clinic, 1001 Blythe Boulevard, Suite 300, Charlotte, North Carolina 28203. (Email: Charles.Simonton{at}carolinashealthcare.org).
Objectives: The purpose of this study was to compare the 9-month clinical outcomes of patients treated with paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES) for coronary artery stenosis.
Background: The STENT (Strategic Transcatheter Evaluation of New Therapies) registry is the first multicenter registry in the U.S. to collect long-term outcomes of drug-eluting stents from "real-world" practice.
Methods: Data on all percutaneous coronary interventions in 8 U.S. hospital centers were collected in the STENT registry between 2003 and 2005. In this prospective, nonrandomized, observational study, the choice of procedures was at the physicians' discretion. Patients who only received a PES (n = 4,671) or SES (n = 4,555) and completed 9-month follow-up (93.8% of eligible) were included for analysis. Primary end points were death, myocardial infarction (MI), and target vessel revascularization (TVR) at 9 months. Secondary outcomes included major adverse cardiac events (MACE) (any of the 3 primary end points) and stent thrombosis.
Results: At 9 months, death, MI, and TVR occurred in 2.2%, 2.0%, and 4.1%, respectively, of the PES group and 2.5%, 2.2%, and 4.3%, respectively, of the SES group (p = NS); MACE occurred in 7.5% of the PES group and 8.0% of the SES group (p = 0.37). After adjustments for group differences in baseline characteristics, TVR (hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.70 to 1.32; p = 0.26) and MACE (HR 0.95, 95% CI 0.81 to 1.12; p = 0.56) were similar for PES and SES. Stent thrombosis at 9 months occurred in 0.7% of both groups.
Conclusions: The results of this study show that clinical restenosis and MACE events after PES and SES procedures in "real-world" patients are infrequent and similar at 9 months.
|
Abbreviations and Acronyms
| | MACE = major adverse cardiac events | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | PES = paclitaxel-eluting stent(s) | | SAT = subacute stent thrombosis | | SES = sirolimus-eluting stent(s) | | ST = stent thrombosis | | TVR = target vessel revascularization |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2007 50: A29-A30.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S.-H. Her, K. D. Yoo, C.-S. Park, D.-B. Kim, J.-M. Lee, P. J. Kim, H.-Y. Kim, K. Chang, D. S. Jeon, W. S. Chung, et al.
Long-term clinical outcomes of overlapping heterogeneous drug-eluting stents compared with homogeneous drug-eluting stents
Heart,
September 15, 2011;
97(18):
1501 - 1506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Schafer, M. T. Sacrinty, D. J. Cohen, M. A. Kutcher, S. K. Gandhi, R. M. Santos, W. C. Little, and R. J. Applegate
Cost-Effectiveness of Drug-Eluting Stents Versus Bare Metal Stents in Clinical Practice
Circ Cardiovasc Qual Outcomes,
July 1, 2011;
4(4):
408 - 415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Jain, C. Lotan, I. T. Meredith, F. Feres, R. Zambahari, N. Sinha, M. T. Rothman, and for the E-Five Registry Investigators
Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry
Heart,
June 1, 2010;
96(11):
848 - 853.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Cho, H. M. Yang, K. W. Park, W. Y. Chung, D. J. Choi, W. W. Seo, K. T. Jeong, S. C. Chae, M. Y. Lee, S. H. Hur, et al.
Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of ST-Segment Elevation Myocardial Infarction: With Analyses for Diabetic and Nondiabetic Subpopulation
J. Am. Coll. Cardiol. Intv.,
May 1, 2010;
3(5):
498 - 506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. B. Song, J. Y. Hahn, S. H. Choi, J. H. Choi, S. H. Lee, M. H. Jeong, H. S. Kim, I. W. Seong, J. Y. Yang, S. W. Rha, et al.
Sirolimus- Versus Paclitaxel-Eluting Stents for the Treatment of Coronary Bifurcations: Results From the COBIS (Coronary Bifurcation Stenting) Registry
J. Am. Coll. Cardiol.,
April 20, 2010;
55(16):
1743 - 1750.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hara, M. Nishino, M. Taniike, N. Makino, H. Kato, Y. Egami, R. Shutta, H. Yamaguchi, J. Tanouchi, and Y. Yamada
Difference of Neointimal Formational Pattern and Incidence of Thrombus Formation Among 3 Kinds of Stents: An Angioscopic Study
J. Am. Coll. Cardiol. Intv.,
February 1, 2010;
3(2):
215 - 220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lotan, I. T. Meredith, L. Mauri, M. Liu, M. T. Rothman, and for the E-Five Investigators
Safety and Effectiveness of the Endeavor Zotarolimus-Eluting Stent in Real-World Clinical Practice: 12-Month Data From the E-Five Registry
J. Am. Coll. Cardiol. Intv.,
December 1, 2009;
2(12):
1227 - 1235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Brodie, H. Wilson, T. Stuckey, M. Nussbaum, S. Laurent, B. Bradshaw, A. Humphrey, C. Metzger, J. Hermiller, F. Krainin, et al.
Outcomes With Drug-Eluting Versus Bare-Metal Stents in Saphenous Vein Graft Intervention: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group
J. Am. Coll. Cardiol. Intv.,
November 1, 2009;
2(11):
1105 - 1112.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Novack, D. Cutlip, N. Kleiman, M. Pencina, L. Mauri, C.-H. Yen, P. Berger, S. Goldberg, M. Kellett, R. Waksman, et al.
In-Hospital and 1-Year Outcomes Among Unselected Percutaneous Coronary Intervention Patients Treated With Either Sirolimus- or Paclitaxel-Eluting Stents: Results From the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) Registry
J. Am. Coll. Cardiol. Intv.,
August 1, 2009;
2(8):
767 - 775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Brodie, T. Stuckey, W. Downey, A. Humphrey, B. Bradshaw, C. Metzger, J. Hermiller, F. Krainin, S. Juk, B. Cheek, et al.
Outcomes and Complications With Off-Label Use of Drug-Eluting Stents: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group
J. Am. Coll. Cardiol. Intv.,
August 1, 2008;
1(4):
405 - 414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2355 - 2369.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the Year in JACC 2007
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
